Contents
- 1 🏥 Hannah Joseph Hospital IPO – Live Analysis Hub
- 1.1 📌 IPO Snapshot
- 1.2 📊 Reservation Structure (SME)
- 1.3 📊 Subscription Status (Live)
- 1.4 📊 GMP History
- 1.5 🏥 Business Overview
- 1.6 💰 Financial Performance (₹ Cr)
- 1.7 📊 Balance Sheet Snapshot (FY25)
- 1.8 💵 Cash Flow Snapshot (FY25)
- 1.9 📊 Valuation Metrics
- 1.10 🎯 Listing Scenario Model
- 1.11 ✅ Strengths vs ⚠️ Risks
- 1.12 📊 Risk–Reward Score
- 1.13 🏁 Final Verdict
🏥 Hannah Joseph Hospital IPO – Live Analysis Hub
Live Market Desk – 6 February Update
Grey Market Premium remains muted at around ₹0–₹1, reflecting cautious sentiment among market participants. Demand patterns indicate that healthcare SME IPOs generally see selective participation rather than aggressive oversubscription, especially in the early days of bidding.
Institutional and high-net-worth investor activity will be critical in the final phase of the issue. The closing day subscription trend is expected to determine pricing strength and listing momentum.
Capital Flow Insight:
If overall subscription crosses the 2.5×–4× range by Day 3, listing sentiment may improve. However, if demand remains below this band, a flat or near-issue-price listing is more likely.
📌 IPO Snapshot
| Issue Size | ₹39.90 Crore (Fresh Issue) |
| Total Shares Offered | ~57,00,000 Shares |
| Price Band | ₹67 – ₹70 |
| Lot Size | 2,000 Shares |
| Minimum Investment | ₹1,40,000 |
| IPO Open | 22 Jan 2026 |
| IPO Close | 27 Jan 2026 |
| Listing Date | 30 Jan 2026 (Expected) |
| Exchange | BSE SME |
| Registrar | Bigshare Services Pvt Ltd |
| Lead Manager | Beeline Capital Advisors Pvt Ltd |
| Post-IPO Market Cap | ₹399 Cr (Approx) |
📊 Reservation Structure (SME)
| QIB | 50% |
| NII / HNI | 15% |
| Retail | 35% |
📊 Subscription Status (Live)
| Category | Day 1 | Day 2 | Final (Expected) |
|---|---|---|---|
| Retail | 0.42x | Updating | 1.5x – 2.5x |
| NII / HNI | 1.10x | Updating | 2.5x – 4.5x |
| QIB | 0.00x | Updating | 0.5x – 1.5x |
| Total | 0.63x | Updating | 2x – 3.5x |
📊 GMP History
| Date | GMP (₹) | Trend |
|---|---|---|
| 20 Jan 2026 | ₹1 | Neutral |
| 21 Jan 2026 | ₹1 | Stable |
| 22 Jan 2026 | ₹0 | Weak |
🏥 Business Overview
Hannah Joseph Hospital operates a multi-specialty healthcare facility providing tertiary care services including surgery, diagnostics, ICU, emergency care, and outpatient services. Revenue growth depends on patient volume, occupancy rates, service mix, and cost efficiency.
💰 Financial Performance (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 52.3 | 64.8 | 78.9 |
| PAT | 2.14 | 3.06 | 4.12 |
| EBITDA Margin | 21.4% | 22.6% | 23.8% |
📊 Balance Sheet Snapshot (FY25)
| Total Assets | ₹145 Cr |
| Net Worth | ₹58 Cr |
| Total Debt | ₹42 Cr |
💵 Cash Flow Snapshot (FY25)
| Operating Cash Flow | ₹6.2 Cr |
| Investing Cash Flow | -₹4.8 Cr |
| Financing Cash Flow | ₹3.1 Cr |
📊 Valuation Metrics
| EPS (Post IPO) | ₹4.7 – ₹5.0 |
| P/E Ratio | ~14x – 15x |
| ROE | 22% – 24% |
| ROCE | 25% – 27% |
| Debt-to-Equity | 0.70 – 0.80 |
🎯 Listing Scenario Model
| Bear Case | ₹65 – ₹69 |
| Base Case | ₹70 – ₹76 |
| Bull Case | ₹77 – ₹90 |
✅ Strengths vs ⚠️ Risks
Strengths
- Stable healthcare demand
- Consistent revenue growth
- Essential service business model
- Improving margins
Risks
- SME liquidity risk
- High operating costs
- Limited scalability
- Dependence on patient volume
📊 Risk–Reward Score
| Business Quality | 6.9 / 10 |
| Growth Visibility | 7.1 / 10 |
| Valuation Comfort | 6.6 / 10 |
| Listing Gain Probability | 25% – 40% |
| Overall Risk Level | High (SME IPO) |
🏁 Final Verdict
Hannah Joseph Hospital IPO reflects neutral sentiment with nil GMP and moderate subscription expectations. Fundamentals are stable, but SME liquidity risk and muted demand suggest limited listing upside unless final-day subscription spikes.
- Listing traders: Apply selectively
- High-risk investors: Small exposure only
- Conservative investors: Avoid
Overall Verdict: ⚖️ High-risk SME IPO with limited upside unless demand strengthens.
Shubham tracks Indian equity markets with a focus on banking stocks, insurance companies, and long-term value investing. PositionalCalls was built to give independent investors the same quality of research that institutional desks produce — in plain language, with no brokerage bias and no paid promotions. All analysis is sourced from RBI, SEBI, NSE/BSE filings, and company annual reports.